On March 19, the FDA approved Zulresso (brexanolone) injection for intravenous (IV) use for the treatment of postpartum depression. Zulresso will be available only through a restricted program…
Reader Survey
Please share your feedback! We’re interested to learn more about your experience with American Nurse Journal.